Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.
/in Dendritic Cells, Glioblastoma, International PublicationsThe final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
/in Dendritic Cells, Glioblastoma, International PublicationsCorrelation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
/in Dendritic Cells, Glioblastoma, International PublicationsIntegration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
/in Dendritic Cells, Glioblastoma, International PublicationsNewcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
/in Glioblastoma, International Publications, Newcastle Disease VirusClinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsImmunotherapy for glioma: getting closer to the clinical arena?
/in Dendritic Cells, Glioblastoma, International PublicationsTherapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer